Loading organizations...
Key people at Innocoll Biotherapeutics.
Innocoll Biotherapeutics develops specialized biodegradable and bioresorbable pharmaceutical products and medical devices. The company's primary offering, XARACOLL, is a bupivacaine HCl collagen-matrix implant designed for localized, sustained postsurgical pain relief. Utilizing a proprietary collagen-based technology platform, Innocoll's solutions are engineered to be fully integrated and naturally absorbed by the body, eliminating the need for subsequent surgical removal.
Founded in 1985, the company began with a core insight into the therapeutic potential of collagen as a natural, bioresorbable matrix for drug delivery and medical applications. This foundational principle guided the development of its unique platform, enabling controlled release of active pharmaceutical ingredients directly at the site of need. The initial focus was on leveraging this innovative material science for various medical uses.
Innocoll's products address significant unmet medical needs for patients undergoing surgical procedures. The company envisions a future where its bioresorbable drug-device combinations provide enhanced patient recovery and improved therapeutic outcomes, pushing the boundaries of integrated pharmaceutical and medical device innovation.
Innocoll Biotherapeutics is a commercial-stage biotechnology company specializing in pharmaceutical manufacturing, focused on innovative post-surgical pain management solutions using proprietary biocompatible and biodegradable collagen-based products.[1][2][3] It develops late-stage pipeline assets like XARACOLL (bupivacaine HCl implant) and POSIMIR (bupivacaine solution for infiltration), targeting unmet needs in patient care by reducing postoperative pain and opioid reliance, primarily serving hospitals, surgeons, and patients undergoing procedures such as abdominoplasty, arthroscopic subacromial decompression, and hernia repairs.[1][2][3][4] With around 73 employees, $4 million in annual revenue, and over $213.5 million in total funding (including a $125 million round), the company demonstrates growth momentum through positive Phase 3 topline results and peer-reviewed publications on its products' efficacy in pain reduction and opioid sparing.[2][3]
As a portfolio company of Gurnet Point Capital, Innocoll addresses critical healthcare challenges like post-surgical pain, fostering collaboration with medical partners to deliver targeted therapies.[1][2]
Founded in 1985 in Athlone, Ireland, Innocoll began as a global specialty pharmaceutical company dedicated to engineering better medicines via precision collagen-based technologies.[2][3] The company evolved from early development of biocompatible, biodegradable products into a commercial-stage biotech with a focus on late-stage programs for pain management.[1][2] Key pivotal moments include multiple funding rounds totaling $213.5 million, with the largest at $125 million, supporting pipeline advancement.[2] It expanded operations to the U.S. (Princeton, New Jersey) and became a portfolio business of Gurnet Point Capital, achieving commercial traction through studies like BU-002-IM (POSIMIR efficacy in arthroscopic procedures) and INN-CB-024 (XARACOLL Phase 3 success in abdominoplasty).[2][3][4] Specific founders are not detailed in available records, but the company's trajectory reflects a shift toward targeted post-surgical solutions amid opioid crisis pressures.[1][2]
Innocoll rides the opioid-sparing pain management trend in biotech, capitalizing on market forces like rising demand for non-opioid alternatives amid the global opioid crisis and regulatory pushes for better postoperative care.[1][2] Its collagen-based implants align with advances in drug-device combinations and precision medicine, influencing the ecosystem by validating biodegradable delivery systems that reduce systemic side effects and hospital stays.[2][4] Timing is favorable with recent Phase 3 successes (e.g., 2021+ studies) amid growing surgical volumes and healthcare focus on patient outcomes, positioning Innocoll to shape competitive dynamics in a market projected for expansion in targeted therapeutics.[2][3]
Innocoll is poised for potential FDA approvals or expanded indications for XARACOLL and POSIMIR, building on positive Phase 3 data and funding strength to capture share in post-surgical pain.[2][4] Trends like AI-optimized drug delivery and further opioid reduction policies will likely propel its collagen platform, with influence evolving through partnerships and acquisitions in biotech. As Gurnet Point's portfolio asset, expect scaled commercialization and new trials (e.g., diabetic foot or hernia applications), reinforcing its role in patient-centered innovation from its 1985 roots.[1][2][4]
Key people at Innocoll Biotherapeutics.
